» Articles » PMID: 32980496

Signaling Pathways Affected by Mutations Causing Osteogenesis Imperfecta

Overview
Journal Cell Signal
Date 2020 Sep 27
PMID 32980496
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Osteogenesis imperfecta (OI) is a clinically and genetically heterogeneous connective tissue disorder characterized by bone fragility and skeletal deformity. To maintain skeletal strength and integrity, bone undergoes constant remodeling of its extracellular matrix (ECM) tightly controlled by osteoclast-mediated bone resorption and osteoblast-mediated bone formation. There are at least 20 recognized OI-forms caused by mutations in the two collagen type I-encoding genes or genes implicated in collagen folding, posttranslational modifications or secretion of collagen, osteoblast differentiation and function, or bone mineralization. The underlying disease mechanisms of non-classical forms of OI that are not caused by collagen type I mutations are not yet completely understood, but an altered ECM structure as well as disturbed intracellular homeostasis seem to be the main defects. The ECM orchestrates local cell behavior in part by regulating bioavailability of signaling molecules through sequestration, release and activation during the constant bone remodeling process. Here, we provide an overview of signaling pathways that are associated with known OI-causing genes and discuss the impact of these genes on signal transduction. These pathways include WNT-, RANK/RANKL-, TGFβ-, MAPK- and integrin-mediated signaling as well as the unfolded protein response.

Citing Articles

Engineering multifunctional surface topography to regulate multiple biological responses.

Asadi Tokmedash M, Kim C, Chavda A, Li A, Robins J, Min J Biomaterials. 2025; 319:123136.

PMID: 39978049 PMC: 11893264. DOI: 10.1016/j.biomaterials.2025.123136.


The Pathogenetic Role of RANK/RANKL/OPG Signaling in Osteoarthritis and Related Targeted Therapies.

Di Cicco G, Marzano E, Mastrostefano A, Pitocco D, Castilho R, Zambelli R Biomedicines. 2024; 12(10).

PMID: 39457605 PMC: 11505501. DOI: 10.3390/biomedicines12102292.


Piperazine-Derived Bisphosphonate-Based Ionizable Lipid Nanoparticles Enhance mRNA Delivery to the Bone Microenvironment.

Yoon I, Xue L, Chen Q, Liu J, Xu J, Siddiqui Z Angew Chem Int Ed Engl. 2024; 64(3):e202415389.

PMID: 39379320 PMC: 11735871. DOI: 10.1002/anie.202415389.


Bone Quality and Mineralization and Effects of Treatment in Osteogenesis Imperfecta.

Misof B, Fratzl-Zelman N Calcif Tissue Int. 2024; 115(6):777-804.

PMID: 39231826 DOI: 10.1007/s00223-024-01263-8.


Losartan alters osteoblast differentiation and increases bone mass through inhibition of TGF signalling in vitro and in an OIM mouse model.

Morita M, Arshad F, Quayle L, George C, Lefley D, Kalajzic I Bone Rep. 2024; 22:101795.

PMID: 39185375 PMC: 11344016. DOI: 10.1016/j.bonr.2024.101795.